Generics group demands 'immediate and urgent actions' on EU medicines supply

13 March 2020
europe_flag_eu_big

Medicines for Europe, the generics trade association, has made three requests as it attempts to ensure continued drug supply apply across the continent amid the ongoing COVID-19 outbreak.

The group’s members supply 67% of prescription medicines in Europe and are the largest suppliers of critical medicines needed to tackle the pandemic. They have 300 production sites working at full capacity manufacturing finished products and active pharmaceutical ingredients (API).

'This crisis cannot hinge on national protectionism'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics